Breast cancer is the most commonly diagnosed cancer in the US and accounts for the one of the highest rates of cancer related deaths in the country. Fortunately, the rate of deaths has been decreasing significantly in recent years as testing improves and allows for faster and more accurate diagnoses. NeoGenomics understands this crucial need and is at the forefront of the breast cancer testing industry, providing patients and their providers with innovative and individualized testing options.
In this OncLive Reach program, Razelle Kurzrock, MD, CMO, esteemed cancer researcher and Director, Center of Personalized Cancer Therapy at University of California, San Diego Moores Cancer Center, discusses the importance of genomic testing and biomarkers, and how biomarker testing is vastly underutilized for breast cancer. Shari Brown, MD, Director of Molecular Pathology Services at NeoGenomics, details how NeoGenomics offers a wide range of tests all sizes for all stages of cancer, from the NeoTYPE Breast Profile that can identify 60 biomarkers, to the NeoTYPE Discovery Tumor Profile that can identify a comprehensive 336 biomarkers, all to help patients receive the best therapies for their specific case.